ArticleIndian journal of surgical oncology2025
Comparative Retrospective Analysis of Ovarian Cancer Treatment Outcomes: Neoadjuvant Therapy with and without Surgical Intervention.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer, a leading cause of cancer-related mortality among Indian women, is predominantly diagnosed at advanced stages. The efficacy of neoadjuvant chemotherapy (NACT) versus traditional treatment approaches, including surgery, remains a critical area of investigation to improve patient outcomes. This retrospective observational study analyzed 84 patients with advanced ovarian carcinoma (stage IIIC or IV) treated at tertiary care center, Tamil Nadu. It compared survival outcomes between patients receiving NACT alone and those undergoing NACT followed by surgical intervention. Data on demographic characteristics, tumor size, ECOG performance status, menopausal status, ascites fluid cytology, and comorbidities were collected. Kaplan-Meier survival analysis and Cox regression were used for statistical assessment. The study found significant associations between treatment modality and survival outcomes. Tumor size, particularly T3, positive ascitic fluid cytology, and neoadjuvant chemotherapy significantly influenced recurrence risk. The overall survival time had a median of 9 years, and time to recurrence had a median of 8 years. Neoadjuvant chemotherapy, when combined with surgical intervention, demonstrated a potential improvement in survival outcomes. The integration of neoadjuvant chemotherapy with surgical intervention may offer beneficial outcomes for patients with advanced ovarian cancer. This study underscores the importance of tailored treatment approaches, emphasizing the role of NACT in the therapeutic landscape of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.